ArticleDiscover oncology2025
Comparing the diagnostic accuracy of pre-operative genetic testing for thyroid cancer on fine needle aspiration cytology specimens: a systematic review and meta-analysis of diagnostic accuracy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Incremental Diagnostic Value of Cell-Block-Based Targeted BRAF and RAS Testing in TBSRTC Category III-IV Thyroid Nodules: A Single-Center Retrospective Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMolecular genetic tests are increasingly used to determine the need for surgery in thyroid nodules with indeterminate fine-needle aspiration (FNA) cytopathology. However, the accuracy of these tests remains uncertain. This systematic review and meta-analysis analyze the diagnostic performance of molecular testing in pre-operative FNA biopsies from indeterminate thyroid nodules (ITN).
methodsWe searched PubMed, Embase, Web of Science, and the Cochrane Library for relevant studies. The preoperative FNA cytopathology from patients over 14 years old, and the postoperative histopathology results were extracted. It was also essential to include true-positive (TP), false-positive (FP), true-negative (TN), and false-negative (FN) counts, along with genetic testing results. Sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and area under the curve (AUC) were calculated for each molecular panel using a random-effects bivariate model.
resultsOverall, 68 studies (2018–2024) were eligible discussing 7 different panels, from 16 countries. Multigene Point-of-care Test (MPTX v1) demonstrated the strongest ability to rule out malignancies (NLR 0.12; n = 4) and exhibited the highest diagnostic value (DOR 18; n = 4). ThyroSeq v2 Next-Generation Sequencing Test for Thyroid Cancer (ThyroSeq v2) followed with a DOR of 10 (n = 9). The PCR groups(n = 20) could not be merged due to significant methodological heterogeneity.
conclusionThis meta-analysis highlights the role of molecular testing in improving the diagnostic accuracy of indeterminate thyroid nodules, potentially reducing unnecessary surgeries. However, further standardization and validation are needed due to study heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.